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Hepatic cell mobilization 
for protection against ischemic 
myocardial injury
Shu Q. Liu1*, John B. Troy1, Chi‑Hao Luan2 & Roger J. Guillory1,3
The heart is capable of activating protective mechanisms in response to ischemic injury to support 
myocardial survival and performance. These mechanisms have been recognized primarily in the 
ischemic heart, involving paracrine signaling processes. Here, we report a distant cardioprotective 
mechanism involving hepatic cell mobilization to the ischemic myocardium in response to 
experimental myocardial ischemia–reperfusion (MI‑R) injury. A parabiotic mouse model was 
generated by surgical skin‑union of two mice and used to induce bilateral MI‑R injury with unilateral 
hepatectomy, establishing concurrent gain‑ and loss‑of‑hepatic cell mobilization conditions. Hepatic 
cells, identified based on the cell‑specific expression of enhanced YFP, were found in the ischemic 
myocardium of parabiotic mice with intact liver (0.2 ± 0.1%, 1.1 ± 0.3%, 2.7 ± 0.6, and 0.7 ± 0.4% at 1, 3, 
5, and 10 days, respectively, in reference to the total cell nuclei), but not significantly in the ischemic 
myocardium of parabiotic mice with hepatectomy (0 ± 0%, 0.1 ± 0.1%, 0.3 ± 0.2%, and 0.08 ± 0.08% 
at the same time points). The mobilized hepatic cells were able to express and release trefoil factor 
3 (TFF3), a protein mitigating MI‑R injury as demonstrated in  TFF3−/− mice (myocardium infarcts 
17.6 ± 2.3%, 20.7 ± 2.6%, and 15.3 ± 3.8% at 1, 5, and 10 days, respectively) in reference to wildtype 
mice (11.7 ± 1.9%, 13.8 ± 2.3%, and 11.0 ± 1.8% at the same time points). These observations suggest 
that MI‑R injury can induce hepatic cell mobilization to support myocardial survival by releasing TFF3.
Ischemic myocardial injury can activate cardioprotective mechanisms to support cardiomyocyte survival and 
mitigate myocardial  infarction1–8. The biological basis of these cardioprotective mechanisms is the cell-survival 
supporting  systems. These systems have possibly developed through evolution in response to environmental 
insults, such as physical, chemical, and microbiological  injuries8. To date, most cardioprotective systems have 
been found within the heart, involving various signaling pathways that can be activated by ischemic cell-released 
paracrine factors such as  adenosine9–11,  bradykinin12,13,  opioids14–16, and/or growth-regulatory  factors17–21. In 
this report, we demonstrate a distant cardioprotective mechanism involving the liver, an organ capable of dis-
charging its cells to the circulatory system in response to experimental myocardial ischemia–reperfusion (MI-R) 
 injury22. The discharged hepatic cells were able to mobilize to the ischemic myocardium to exert a protective 
action by releasing trefoil factor 3 (TFF3), an endocrine protein known to support cardiomyocyte  survival23. 
The significance of hepatic cell mobilization is to support the paracrine cardioprotective mechanisms, thereby 
augmenting cardioprotection.
Hepatic cell mobilization is an acute, transient process occurring after ischemic myocardial  injury22. Given 
its relationship with myocardial ischemia, hepatic cell mobilization has been considered a process contributing 
to  cardioprotection22. However, it has been difficult to confirm its cardioprotective role because of difficulties in 
establishing a loss-of-hepatic cell mobilization condition in an animal model. An effective approach is to remove 
the liver of an animal to eliminate hepatic cell mobilization; however, this approach causes rapid animal death. 
To overcome such a problem, a parabiotic mouse model (surgical skin-union of two mice) was developed and 
used to induce MI-R injury in both mice while the liver was removed in one mouse, providing a gain-of-hepatic 
cell mobilization condition in the mouse with intact liver and a concurrent loss-of-hepatic cell mobilization 
condition in the mouse with hepatectomy. As the mobilized hepatic cells in the mouse with the intact liver were 
not able to reach the mouse with hepatectomy, this model was used to evaluate the cardioprotective role of the 
mobilized hepatic cells by analyzing experimental outcomes in the presence and absence of hepatic cells in the 
ischemic myocardium.
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A fundamental question is how the mobilized hepatic cells contribute to cardioprotection in MI-R injury. 
One potential mechanism is to release cardioprotective factors directly from the hepatic cells recruited to the 
ischemic myocardium, an approach conceivably more effective than distant release from the liver. The liver has 
been shown to upregulate and release the endocrine factor  TFF323, a protein originally identified in intestinal 
epithelial cells and recognized as a protective factor against endothelial injury under physiological and patho-
logical  conditions24–29. Ischemic myocardial injury has been shown to stimulate the expression of TFF3 in the 
hepatic  cells23. TFF3 was able to mitigate ischemic myocardial injury in a mouse model with recombinant TFF3 
 administration23. However, the cardioprotective role of TFF3 has not been confirmed by using a genetically 
modified model. The present investigation was designed to demonstrate the mechanisms by which the mobilized 
hepatic cells were able to protect the ischemic myocardium by releasing TFF3 and confirm the cardioprotective 
role of TFF3 by using a  TFF3−/− mouse model with and without recombinant TFF3 administration.
Results
Mobilization of hepatic cells to the circulatory system and ischemic myocardium. Hepatic cells 
were mobilized to the circulatory system in response to MI-R injury, as demonstrated by using the mouse model 
expressing hepatic cell-specific eYFP (enhanced yellow fluorescent protein)22. Circulating eYFP-positive hepatic 
cells were found in the left ventricular chamber at 1 day, reached a peak population at 5 days, and returned 
toward the sham control level at 10 days after MI-R injury (Fig. 1A,B). The mobilized eYFP-positive hepatic 
cells were recruited to the ischemic, but not the intact and sham-control, myocardium with a peak population at 
5 days after MI-R injury as detected by fluorescence microscopy (Fig. 1A,C; supplementary Fig. 1 and Table 1).
The presence of eYFP-positive hepatic cells in the ischemic myocardium was confirmed by immunohisto-
chemistry with an anti-eYFP antibody (Fig. 2A). The ischemic myocardium-recruited eYFP-positive cells did 
not express the leukocyte marker CD45 (Fig. 2B). Unilateral hepatectomy in parabiotic mice did not significantly 
influence leukocyte recruitment to the ischemic myocardium (supplementary Table 2). Selected eYFP-positive 
cells (23 ± 9% in reference to the total eYFP-positive cells) in the ischemic myocardium expressed cytokeratin 19, 
a protein marker used for identifying hepatic biliary epithelial cells in the liver (Fig. 2C, supplementary Table 3). 
These observations suggest that hepatocytes and biliary epithelial cells can be mobilized to the circulatory system 
and ischemic myocardium in response to MI-R injury.
The parabiotic mouse model with bilateral MI-R injury and unilateral hepatectomy demonstrated uneven 
distributions of the mobilized eYFP-positive hepatic cells in the circulatory system and ischemic myocardium 
between the liver-intact and hepatectomized parabiotic mice. Whereas hepatic cells were present in the left 
ventricular chamber and ischemic myocardium of the liver-intact parabiotic mice in MI-R injury, these cells 
were found at significantly lower levels at the same locations of the hepatectomized parabiotic mice at the same 
time points (Fig. 1; supplementary Table 1). There was no evidence showing exchanges in mobilized hepatic 
cells between the two mice of a parabiotic pair, as shown in a parabiotic model with paired Alb-Cre/eYFP and 
C57BL/6J mice with bilateral MI-R injury and alternated unilateral hepatectomy (supplementary Fig. 2, sup-
plementary Table 4). These observations suggest that the mobilized hepatic cells from the liver-intact mouse 
were not able to reach the hepatectomized mouse in a parabiotic pair. Thus, this parabiotic mouse model can be 
used to establish concurrent gain- and loss-of-hepatic cell conditions in the ischemic myocardium, allowing the 
evaluation of the role of the mobilized hepatic cells in cardioprotection in MI-R injury.
The fate of the mobilized hepatic cells in the circulatory system. The mobilized eYFP-positive 
hepatic cells in MI-R injury were found in the left ventricular chamber (Fig. 1) and ascending aorta (supplemen-
tary Fig. 3), but not significantly in the distant peripheral arteries and veins, including the femoral artery and 
vein (supplementary Fig. 3). The circulating eYFP-positive hepatic cell population in the ascending aorta was 
about 10 times larger than that in the femoral artery and vein (supplementary Fig. 3). These observations sug-
gested that the circulating hepatic cells were eliminated within the aorta. However, the underlying mechanisms 
remain to be tested.
Role of the mobilized hepatic cells in the mitigation of MI‑R injury. The parabiotic mouse model 
was used to test the role of the mobilized hepatic cells in the mitigation of MI-R injury. In parabiotic mouse pairs 
with bilateral MI-R injury and unilateral hepatectomy, the liver-intact parabiotic mice with mobilized hepatic 
cells showed significantly reduced myocardial infarction compared with hepatectomized parabiotic mice at all 
observation times (Fig. 3). Cardiac sham operation did not cause myocardial infarction in liver-intact and hepa-
tectomized mice at selected time points (1 and 5 days) (supplementary Fig. 4). Functional analyses showed that 
the levels of left ventricular dp/dt (Fig. 4A,B) and fractional shortening (Fig. 4C,D) were significantly higher in 
the liver-intact parabiotic mice than the levels of the two parameters in the hepatectomized parabiotic mice in 
MI-R injury. However, the left ventricular wall thickness was not significantly different between the liver-intact 
and hepatectomized mice (Supplementary Fig. 5). These observations suggest that the mobilized hepatic cells 
support myocardial survival and performance in MI-R injury.
Hepatic cell transplantation for myocardial protection. To confirm the role of hepatic cells in car-
dioprotection, hepatic cells were prepared from Alb-Cre/eYFP mice and transplanted into the ischemic myocar-
dium of non-parabiotic C57BL/6J mice immediately following coronary artery ligation. eYFP-positive hepatic 
cells were present in the ischemic myocardium, although the density of these cells gradually declined (Fig. 5). 
This treatment mitigated significantly myocardial infarction at 1, 5, and 10 days of MI-R injury (Fig. 6). These 
observations support the findings from the parabiotic model above and suggest hepatic cell transplantation may 
serve as a potential cardioprotective strategy against ischemic myocardial injury.
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Figure 1.  Mobilization of hepatic cells to the circulatory system and ischemic myocardium in response to MI-R 
injury. (A) eYFP-positive cells from left ventricular blood samples and the ischemic myocardium of liver-intact 
and hepatectomized parabiotic Alb-Cre/eYFP mice. Green: eYFP. Red: Antibody-labeled cardiac troponin I. 
Blue: Hoechst 33258-stained cell nuclei. The length scale is for all panels. (B, C) Graphic representations of 
eYFP-positive cell populations in the left ventricular chamber (B) and ischemic myocardium (C) of liver-intact 
and hepatectomized parabiotic Alb-Cre/eYFP mice. The % of eYFP-positive cells was calculated in reference 
to the total cell nuclei. Solid blue and red circles: Means ± SDs from liver-intact and hepatectomized Alb-Cre/
eYFP mice with MI-R injury, respectively. Open blue and red circles: Raw data points (n = 6) from liver-intact 
and hepatectomized Alb-Cre/eYFP mice with MI-R injury, respectively. The blue colored p values are for 
comparisons between the liver-intact and hepatectomized parabiotic mice by ANOVA. The p value on each 
red-colored column is for a post-hoc comparison between the liver-intact and hepatectomized parabiotic mice 
at each time point.
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Figure 2.  Characterization of hepatic cells in the liver and ischemic myocardium. (A) Confirmation of eYFP-
positive hepatic cells in the liver and ischemic myocardium of Alb-Cre/eYFP mice with 5-day MI-R injury by 
fluorescence and immunohistochemistry microscopy. Each pair of fluorescence and immunohistochemistry 
images was from the same specimen. Green: eYFP. Red: Antibody-labeled cardiac troponin I. Blue: Hoechst 
33,258-stained cell nuclei. Brown: Antibody-labeled eYFP by immunohistochemistry. The length scale is for all 
panels. (B, C) Fluorescence micrographs showing eYFP-positive cells, CD45-positive cells, and cytokeratin 19 
(CK19)-positive cells in the ischemic myocardium of an Alb-Cre/eYFP mouse with 5-day MI-R injury. Note 
co-localization of eYFP with CK19, suggesting the presence of bile ductular epithelial cells.
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Figure 3.  Myocardial infarction in liver-intact and hepatectomized parabiotic mice. (A) Left ventricular 
specimens from liver-intact and hepatectomized parabiotic mice, showing TTC-stained myocardial infarcts 
(pale) at 1 and 3 days and AZAN-stained myocardial infarcts/fibrotic tissue (blue) at 5 and 10 days after 
MI-R injury. Red: Intact myocardium. The length scale is for all panels. (B) Graphic representation of the % 
of myocardial infarcts in reference to the total volume of the left ventricular wall. Solid blue and red circles: 
Means ± SDs from liver-intact and hepatectomized parabiotic mice with MI-R injury, respectively. Open blue 
and red circles: Raw data points (n = 6) from liver-intact and hepatectomized parabiotic mice with MI-R injury, 
respectively. The blue-colored p value is for comparison between the liver-intact and hepatectomized mice by 
ANOVA. The p value on each blue-colored column is for post-hoc comparison between the liver-intact and 
hepatectomized mice at each time point.
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Hepatic cell‑mediated TFF3 delivery to the ischemic myocardium. A fundamental question is 
how the mobilized hepatic cells protect the myocardium from ischemic injury. Given that the hepatic cells can 
express TFF3, an endocrine protein capable of mitigating ischemic myocardial  injury23, one possibility is that the 
hepatic cells recruited to the ischemic myocardium may release TFF3 to protect the myocardium from ischemic 
injury. This possibility was evaluated by analyzing the difference in the relative TFF3 level in the ischemic myo-
cardium between the liver-intact and hepatectomized parabiotic mice. In this model, the relative level of TFF3 in 
the liver of mice with MI-R injury was higher than that in the ischemic myocardium of the same mice (Fig. 7A). 
The relative level of TFF3 in the ischemic myocardium of the liver-intact parabiotic mice (with a higher density 
of mobilized hepatic cells) was substantially higher than that in the ischemic myocardium of the hepatectomized 
parabiotic mice (with a significantly lower density of mobilized hepatic cells) (Fig. 7B). The TFF3 level in the 
ischemic myocardium of hepatectomized parabiotic mice was comparable to that in the sham control myocar-
dium without MI-R injury (Fig. 7B). Similar levels of TFF3 were detected in the ischemic myocardium of para-
biotic mice with bilateral MI-R injury and bilateral hepatic sham operation (without hepatectomy) (Fig. 7B). In 
Figure 4.  Left ventricular (LV) performance analyses in MI-R injury. (A) LV dp/dt recorded from liver-intact 
and hepatectomized parabiotic mice with cardiac sham operation and MI-R injury at 5 days. (B) Graphic 
representations of LV dp/dt and l-dp/dtl (absolute -dp/dt) from liver-intact and hepatectomized parabiotic 
mice with cardiac sham operation and MI-R injury. Solid blue and red circles: Means ± SDs from liver-intact 
and hepatectomized parabiotic mice with MI-R injury, respectively. Open blue and red circles: Raw data points 
(n = 6) from liver-intact and hepatectomized parabiotic mice with MI-R injury, respectively. The blue-colored 
p values are for comparisons between the liver-intact and hepatectomized parabiotic mice by ANOVA. The 
p value on each red-colored column is for post hoc comparison between the liver-intact and hepatectomized 
parabiotic mice at each time point. (C) LV echocardiograms from liver-intact and hepatectomized parabiotic 
mice with cardiac sham operation and MI-R injury at 5 days. (D) Graphic representations of LV fractional 
shortenings from liver-intact and hepatectomized parabiotic mice with cardiac sham operation and MI/R injury. 
Solid blue and red circles: Means ± SDs from liver-intact and hepatectomized parabiotic mice with MI-R injury, 
respectively. Open blue and red circles: Raw data points (n = 6) from liver-intact and hepatectomized parabiotic 
mice with MI-R injury, respectively. The blue-colored p value is for comparison between the liver-intact and 
hepatectomized parabiotic mice by ANOVA. The p value on each red-colored column is for comparison 
between the liver-intact and hepatectomized parabiotic mice at each time point.
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cardiac sham-control parabiotic mice, unilateral hepatectomy did not influence the relative level of TFF3 in the 
myocardium (supplementary Fig. 6). These observations suggest a potential role for the mobilized hepatic cells 
in the delivery of TFF3 to the ischemic myocardium.
Role of TFF3 in myocardial protection. To demonstrate the cardioprotective role of TFF3, MI-R injury 
was introduced to non-parabiotic  TFF3−/− mice with wildtype mice as the control. As shown in Fig.  8, the 
 TFF3−/− mice showed significantly higher levels of myocardial infarction at 1, 5, and 10 days after MI-R injury 
than the wildtype mice. Administration of recombinant TFF3 to the ischemic myocardium of the  TFF3−/− mice 
immediately after coronary artery ligation increased the level of TFF3 in the ischemic myocardium (supplemen-
tary Fig. 7) and significantly reduced the level of myocardial infarction in reference to that with PBS administra-
tion (Fig. 8). These results confirmed previous observations about the cardioprotective role of  TFF323.
Discussion
Significance of hepatic cell mobilization in MI‑R injury. Myocardial ischemia is a life-threatening 
condition. Various molecular and cellular systems have evolved to protect the heart from ischemic  injury7,8. It 
has long been recognized that there exist regional or paracrine protective mechanisms within the heart, involv-
ing cell survival-supporting signaling pathways that can be activated by ischemic cell-released ligands such as 
 adenosine9–11,  bradykinin12,13,  opioids14–16, vascular endothelial growth  factor19,20, and follistatin-like protein 
 130,31. The present investigation has identified an additional cardioprotective mechanism – mobilization of 
hepatic cells to the ischemic myocardium to deliver TFF3, a secreted protein capable of supporting myocardial 
survival. Although the mechanisms of TFF3 action remain to be investigated, this discovery suggests the pres-
Figure 5.  eYFP-positive hepatic cells transplanted to the myocardium of C57BL/6J mice with and without 
MI-R injury. (A) Fluorescence micrographs showing eYFP-positive hepatic cells (green) in the liver and isolated 
eYFP-positive hepatic cells in PBS placed on a microscope glass slide covered with a coverslip (note that almost 
all isolated hepatic cells were eYFP-positive). The length bar is for both images. (B) Fluorescence micrographs 
showing eYFP-positive hepatic cells (green) transplanted into the myocardium of a healthy mouse and into 
the ischemic myocardium core of mice with MI-R injury. Red: Antibody-labeled cardiac troponin I. Blue: 
Cell nuclei for both panels A and B. (C) Graphic representation of the density of eYFP-positive hepatic cells 
transplanted to the myocardium of C57BL/6J mice. Means and SDs are presented (n = 6). The solid and open 
circles represent the means and individual data points.
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ence of a liver-based distant process for protection against myocardial injury under an ischemic attack. In addi-
tion to the liver, the bone marrow and spleen can discharge hematopoietic cells into the circulatory system to aid 
in cardioprotection in response to ischemic myocardial  injury32–37. It seems that the distant mechanisms are an 
integral part of the cardioprotective system, acting together with the regional cardioprotective mechanisms to 
augment myocardial survival under an ischemic insult. The involvement of multiple organs in cardioprotection 
conforms to the labor-division mechanism in multi-celled organisms—the collaborative action of multiple cell 
types or organs to help implement or support a function designated to a selected cell type or  organ8. In ischemic 
Figure 6.  Mitigation of myocardial infarction in response to hepatic cell transplantation. (A) Left ventricular 
(LV) specimens at day 1 of MI-R were treated with TTC for showing acute myocardial infarcts (pale) and 
LV specimens at day 5 and 10 of MI-R were stained with orange red and methylene blue (AZAN assay) for 
demonstrating myocardial fibrosis (blue) in mice with and without hepatic cell transplantation. (B) Graphic 
representation of the influence of hepatic cell transplantation on the level of myocardial infarction. Solid red and 
blue circles: Means ± SDs from individual mice without and with hepatic cell transplantation, respectively. Open 
red and blue circles: Raw data points (n = 6) from individual mice without and with hepatic cell transplantation, 
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myocardial injury, a cardioprotective labor-division mechanism reduces the burden to the injured cardiac cells 
that are incapable of implementing all designated functions, including protective gene expression, and helps to 
prevent heart failure.
Hepatic cell mobilization-mediated TFF3 delivery to the ischemic myocardium represents an example sup-
porting the cardioprotective labor-division mechanism. Cardiac cells express a substantially lower level of TFF3 
compared with hepatic cells under sham control and ischemic conditions as shown in this investigation. The 
mitigation of myocardial injury in response to hepatic cell mobilization-induced elevation in the myocardial 
TFF3 level suggests the necessity of endocrine TFF3 for cardioprotection. TFF3 has been originally found in the 
intestinal epithelial cells and known as a protective factor against intestinal epithelial injury under healthy and 
pathological  conditions24–29. TFF3 is also upregulated and released from the liver to protect the brain from injury 
in response to experimental ischemic  stroke38. Thus, TFF3 serves potentially as a protective factor for multiple 
organ systems. The delivery of TFF3 to the ischemic myocardium by hepatic cell mobilization may represent a 
more effective approach for reaching a critical cardioprotective level than TFF3 delivery from the liver through 
the circulatory system.
The necessity of the parabiotic model. Mouse parabiosis, the surgical union of two mice through a skin 
connection to establish cross-animal circulatory communications, was used as a model in this investigation to 
demonstrate the cardioprotective action of the mobilized hepatic cells. Although parabiosis adds another layer 
of complexity to the MI-R injury model, it is necessary to use such a model to establish loss- and gain-of-hepatic 
cell mobilization conditions. A simple, effective approach to eliminate hepatic cell mobilization in an animal 
model is to remove the liver; however, such an approach causes rapid animal death. A parabiotic model allows 
the removal of a single liver from a parabiotic pair. The remaining liver is sufficient to support both mice. This 
modification establishes a condition with hepatic cell mobilization in the liver-intact mouse. As the mobilized 
hepatic cells are eliminated through the aorta and cannot reach the circulatory system of the parabiotic partner 
mouse with hepatectomy, hepatic cells can only be recruited to the heart of the liver-intact mouse, but not to 
the heart of the hepatectomized mouse, establishing concurrent gain- and loss-of-hepatic cell conditions in the 
Figure 7.  Relative levels of TFF3 in the liver (hepatic cells) and ischemic myocardium. (A) Immunoblot 
analysis of relative TFF3 levels in hepatic cells (H) and the left ventricular myocardium (V) of the liver-intact 
parabiotic mice with MI-R injury, showing distinct TFF3 levels between the hepatic cells and the ischemic 
myocardium of the same mouse at each time point. M: Molecular weight markers. (B) Immunoblot analysis of 
relative TFF3 levels in the ischemic myocardium of the liver-intact ( +) and hepatectomized (–) parabiotic mice 
with bilateral MI-R injury, showing distinct TFF3 levels between the liver-intact and hepatectomized parabiotic 
mice. For both panels A and B, β actin was used as a loading control. Immunoblot images were from cropped 
blots. Images from full-length blots are included in the supplementary file.
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same parabiotic pair. Thus, this model can be used to evaluate the role of the mobilized hepatic cells in protection 
against ischemic myocardial injury.
Regulation of hepatic cell mobilization. Hepatic cell mobilization is regulated by endocrine signaling 
mechanisms activated in response to MI-R injury, involving interleukin (IL) 6 released primarily from leuko-
cytes recruited to the ischemic  myocardium22. IL6, a major inflammatory regulatory  factor39, can enter the cir-
culatory system to activate leukocytes, enabling leukocytes to extravasate to the hepatic  parenchyma22. The liver-
retained leukocytes can express and release MMP2, a proteinase capable of degrading the collagen matrix. These 
activities cause dissociation of hepatic cells nearby the liver-retained  leukocytes22. The dissociated hepatic cells 
can be discharged into the circulatory system. An interesting observation was that the hepatic cells immediately 
mobilized to the hepatic central veins are often clustered with leukocytes, which dissociate from the mobilized 
hepatic cells in the vena cava under the influence of blood  flow22. These observations support the presence of sys-
Figure 8.  TFF3-mediated mitigation of myocardial infarction. (A) Left ventricular specimens treated with TTC 
for demonstrating acute myocardial infarcts (pale) at day 1 of MI-R injury and stained with orange red and 
methylene blue (AZAN assay) for showing myocardial fibrosis (blue) at day 5 and 10 of MI-R injury in wildtype 
and  TFF3−/− mice with PBS and recombinant TFF3 administrations into the ischemic myocardium immediately 
after coronary artery ligation. (B) Graphic representation of the influence of TFF3 on the level of myocardial 
injury. Solid dark gray, red, and blue circles: Means ± SDs from wildtype mice and  TFF3−/− mice with PBS and 
recombinant TFF3 administrations, respectively. Open dark gray, red, and blue circles: Raw data points (n = 6) 
from individual wildtype mice and  TFF3−/− mice with PBS and recombinant TFF3 administrations, respectively. 
The dark gray-colored p value at each time point is for comparison between the wildtype mice and  TFF3−/− mice 
with PBS administration. The blue-colored p value at each time point is for comparison between  TFF3−/− mice 
with PBS and recombinant TFF3 administrations.
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tems signaling mechanisms between the heart and liver for the activation of distant cardioprotective processes 
in response to ischemic myocardial injury.
The fate of the mobilized hepatic cells. Hepatic cell mobilization is a transient process, occurring pri-
marily within 10 days after MI-R injury. At the observation time points 1, 3, 5, and 10 days after MI-R injury, the 
mobilized hepatic cells were present in the left ventricular chamber and the ascending aorta, but absent in the 
peripheral arteries and veins. Although it is unclear what causes the elimination of the mobilized hepatic cells 
within the aorta, it is possible to speculate that blood flow-associated fluid shear stress may play a role. The aortic 
fluid shear stress, the highest through the longest large blood vessel, may cause disintegration of the mobilized 
hepatic cells, a cell type not subject to a high fluid shear stress environment under physiological conditions and 
thus susceptible to mechanical injury. However, this speculation requires experimental verification. As hepatic 
cells are not circulatory cells, their rapid clearance prevents hepatic cell accumulation in the circulatory system. 
The hepatic cells recruited to the ischemic myocardium were present up to 10 days. The population of hepatic 
cells in the ischemic myocardium reached a peak at day 5 and returned toward the sham-control level at day 10. 
This time course was coincident with that of acute ischemic myocardial injury. These observations suggest that 
hepatic cell mobilization is induced for myocardial protection in response to acute ischemic injury. However, the 
fate of the hepatic cells recruited to the ischemic myocardium remains to be investigated.
Regulation of TFF3 expression. An important question is how the heart communicates with the liver in 
MI-R injury to cause TFF3 expression. A previous report has suggested that the cytokine IL6 may play a role 
in stimulating TFF3 expression in the  liver22. IL6 is upregulated and released from leukocytes recruited to the 
ischemic myocardium and can enter the circulatory  system22. This cytokine may stimulate hepatic cell expression 
of TFF3 as the mouse TFF3 gene promoter/enhancer region contains binding sites for  STAT321, a transcription 
factor mediating IL6-induced gene  expression40,41. Indeed, IL6 has been shown to stimulate TFF3 expression via 
the mediation of STAT3 in gastrointestinal epithelial  cells40 and biliary epithelial  cells41,42. Although IL6 causes 
TFF3 expression, this cytokine was not used to stimulate TFF3 expression in this investigation because IL6 itself 
is a cardioprotective factor and can activate various inflammatory responses that complicate data interpretation 
for the cardioprotective action of TFF3.
Technical concerns. There are several technical concerns for this investigation. The mechanisms of TFF3 
action remain poorly understood. A TFF3 receptor and associated signaling pathway(s) have not been identi-
fied in cardiomyocytes. Given the cardioprotective role of TFF3, it would be interesting to study the signaling 
mechanisms of TFF3 in ischemic myocardial injury. The Evans blue-based measurement of the area-at-risk is 
often conducted and used as a reference to evaluate the relative level of acute myocardial infarction identified 
by the TTC assay. This approach was not used in this investigation because two different assays were used to 
evaluate myocardial infarction—the TTC assay for 1- and 3-day analyses and the AZAN assay for 5- and 10-day 
analyses. It is difficult to measure accurately the area-at-risk by the Evans blue assay at 5 and 10 days of MI-R 
injury because of the presence of newly generated blood vessels that perfuse the ischemic myocardium, resulting 
in false negative estimation of the area-at-risk. The TTC assay, designed to detect live and dead cells, was not 
used for the 5- and 10-day analysis of myocardial infarction because of the presence of leukocytes and regener-
ated fibroblasts in the ischemic myocardium, causing false negative measurement of myocardial infarction. The 
AZAN assay, designed to detect the infarcted myocardium based on the presence of fibrotic tissue, is not suitable 
for identifying acute myocardial infarction at 1 and 3 days prior to fibrosis. Given these technical limitations, 
it is difficult to use either the TTC or AZAN assay for all observation time points. To establish a common basis 
for comparison in myocardial infarction by using both TTC and AZAN assays, coronary artery ligation was 
conducted at the same location—the second diagonal branch bifurcation point for all mice tested at all time 
points. This location was consistent among mice tested in this investigation in terms of the relative distance of 
the ligation site to the cardiac apex.
Concluding remarks
Ischemic myocardial injury has long been known to activate regional signaling mechanisms that protect the 
cardiomyocyte from death. This investigation demonstrated that the liver was able to respond to MI-R injury 
to mobilize its cells to the circulatory system and ischemic myocardium for mitigating myocardial infarction by 
releasing the cardioprotective factor TFF3. These findings suggest the presence of distant cardioprotective mecha-
nisms that act in concert with the regional mechanisms to augment myocardial survival under an ischemic attack.
Materials and methods
Animal models. Alb-Cre/eYFP, C57BL/6J,  TFF3−/−, and 129S1/SvImJ mice, 2-month old and male, were 
used in this investigation. The Alb-Cre/eYFP mice were used to induce the expression of enhanced yellow/green 
fluorescence protein (eYFP) in hepatic cells, including hepatocytes and bile ductular epithelial cells, allowing 
the identification of hepatic cells mobilized to the circulatory system and ischemic  myocardium22. These mice 
were generated by crossing the mouse strain B6.Cg-Tg(Alb-cre)21Mgn/J (C57BL/6J background, Jackson Labo-
ratory) expressing the Alb-Cre gene (albumin gene promoter-driven Cre recombinase gene) with the mouse 
strain B6.129X1-Gt(ROSA)26-Sortm1(EYFP)Cos/J (C57BL/6J background, Jackson Laboratory) expressing the eYFP 
gene controlled by a loxP-flanked stop sequence that blocks eYFP expression in the lack of Cre recombinase. 
The Cre recombinase, specifically expressed in the liver driven by the albumin gene promoter, can delete the 
stop sequence for the eYFP gene between the loxP sites, resulting in hepatic cell-specific expression of eYFP. 
This model was used to identify hepatic cells mobilized to the circulatory system and ischemic myocardium in 
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MI-R injury by fluorescence microscopy and immunohistochemistry with an anti-eYFP antibody (Clontech). 
C57BL/6J mice were used as a control. The  TFF3−/− mice (129;B6-Tff3tm1Dkpy/J, 129S1/SvImJ background, Jack-
son Laboratory) were used to evaluate the cardioprotective role of TFF3 in MI-R injury with 129S1/SvImJ mice 
as a control. Experimental procedures were approved by the Northwestern University Animal Care and Use 
Committee. The study on mice was carried out in compliance with the “Guide for the Care and Use of Labora-
tory Animals” by the National Research Council, USA and the guidelines of ARRIVE (Animal Research: Report-
ing of In Vivo Experiments).
Myocardial ischemia–reperfusion injury. Myocardial ischemia–reperfusion (MI-R) injury was induced 
in mice by 30-min ligation of the left anterior descending coronary artery at the second diagonal branching point 
as  described23,43. Gender- and body weight-matched mice with sham operation were used as controls. The ani-
mals were examined at 1, 3, 5, and 10 days. These time points were selected based on the time course of hepatic 
cell mobilization in response to ischemic myocardial  injury22. The sample size of each group was determined by 
power analysis.
Parabiosis. A parabiotic mouse model was established by connecting the lateral skins of two male, 2-month 
old, size-matched Alb-Cre/eYFP mice from the same litter. In this model, blood flow communication can be 
established between the two parabiotic mice within 2  weeks44,45. This model was used to introduce concurrent 
gain- and loss-of-hepatic cell mobilization conditions to the two parabiotic mice by unilateral hepatectomy 
(removing the liver of one parabiotic mouse) and bilateral MI-R injury, allowing the evaluation of the cardiopro-
tective action of the mobilized hepatic cells. MI-R injury was introduced to both mice of each parabiotic pair at 
2 weeks after parabiotic surgery. Immediately following coronary artery ligation, hepatectomy was carried out 
in one of the two parabiotic mice to remove > 90% of the liver (note that it was difficult to remove completely 
the liver because of the short distance between the liver and the vena cava), while a hepatic sham operation was 
performed in the other parabiotic mouse. In this model, the mobilized hepatic cells, while able to reach the heart 
of the liver-intact mouse, were unable to reach the hepatectomized mouse as these cells were rapidly eliminated 
in the aorta, establishing gain- and loss-of-hepatic cell mobilization conditions in the same parabiotic pair. Car-
diac sham operation was introduced to parabiotic mice with unilateral hepatectomy. Left ventricular specimens 
were examined and used as controls at 1 and 5 days. In addition, Alb-Cre/eYFP and C57BL/6J mice were paired 
to establish a parabiotic model for testing hepatic cell exchange between the two mice of each parabiotic pair.
Hepatic cell isolation and transplantation. To confirm the cardioprotective role of hepatic cells, eYFP-
positive hepatic cells were isolated from Alb-Cre/eYFP mice and transplanted to the ischemic myocardium of 
C57BL/6J mice. To isolated hepatic cells, collagenase (0.25% in PBS) was introduce to the liver of Alb-Cre/eYFP 
mice by abdominal aorta perfusion (37 °C, 15 min after deep anesthesia) to cause hepatic cell dissociation. Total 
cells were collected from the collagenase-treated liver and centrifuged in a Percoll medium for isolating hepatic 
 cells23,46. The purity of eYFP-positive hepatic cells was assessed by fluorescence microscopy. The isolated hepatic 
cells (~ 2 ×  105 in 20 µl PBS) were immediately used and injected slowly to 4 locations of the ischemic myocar-
dium of a body weight- and gender-matched C57BL/6J mouse following coronary artery ligation. C57BL/6 J 
mice without hepatic cell transplantation were used as a control. At 1, 5, and 10  days following hepatic cell 
transplantation, myocardial specimens were collected and cut into cryo-sections of 5 μm in thickness. The trans-
planted eYFP hepatic cells in myocardial specimen sections were visualized by fluorescence microscopy. The 
density of these cells (per unit area) in the myocardial specimen sections was measured at 1, 5, and 10 days fol-
lowing myocardial ischemia–reperfusion injury. The level of myocardial infarction was analyzed at these time 
points with 6 mice each time point as describe below.
Recombinant TFF3 administration. To test the role of TFF3 in cardioprotection, recombinant TFF3 
(CYT-781, ProSpec) 50 ng in 20 µl PBS was injected slowly to 4 locations of the ischemic myocardium of a 
 TFF3−/− mouse immediately after coronary artery ligation.  TFF3−/− mice with PBS injection were used as a con-
trol. The level of myocardial infarction was analyzed at 1, 5, and 10 days with 6 mice each time point as described 
below.
Left ventricular dp/dt and echocardiography. The contractile function of the left ventricle was evalu-
ated based on left ventricular fractional shortening by echocardiography and left ventricular dp/dt by analyzing 
the first derivative of blood pressure. A SonoScape ultrasound system and a Millar micro-catheter pressure 
transducer system were used for these measurements, respectively, as  described23,43.
Microscopy. Blood samples of 20 µl each were collected from the left ventricular chamber, ascending aorta, 
femoral artery, and femoral vein of each anesthetized mouse, smeared on glass slides, treated with Hoechst 
33,258 for staining cell nuclei, and used to count EYFP-positive cells by fluorescence microscopy. The relative 
density of EYFP-positive cells was calculated in reference to the total number of cell nuclei. The heart of a fully 
anesthetized mouse was perfused with 4% formaldehyde in PBS for 30 min, cut into cryo-sections of 10 µm in 
thickness, and tested by fluorescence microscopy to identify EYFP-positive cells. The same blood and cardiac 
specimens were also tested by immunohistochemistry with a primary anti-EYFP antibody and a horseradish 
peroxidase-conjugated secondary antibody to confirm the identity of the fluorescence microscopy-detected 
EYFP-positive cells. There are two hepatic cell types that express EYFP – hepatocytes and bile ductular cells. 
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The bile ductular epithelial cells were identified based on co-expression of EYFP and cytokine 19 (CK19), a bile 
ductular cell-specific marker within the liver.
Assessment of myocardial infarction. The level of myocardial infarction was assessed by using the TTC 
assay at 1 and 3 days and AZAN assay at 5 and 10 days. The TTC assay was not used at 5 and 10 days because of 
the presence of leukocytes and fibroblasts that show positive (red) TTC staining in the infarcted myocardium. 
The AZAN assay was used at 5 and 10 days to stain fibrotic tissue. For the TTC assay, the heart was removed rap-
idly from a euthanized mouse, frozen at − 90 °C for 5 min, and cut into 0.5 mm-thick serial slices, stained with 
1% TTC in PBS at 37 °C for 30 min, and examined by microscopy. For the AZAN assay, the heart was perfused 
with 4% formaldehyde in PBS for 30 min, cut into 20 µm-thick serial sections by using a cryo-microtome, and 
stained with AZAN solutions as  described23,43. The fraction of myocardial infarcts was measured in both TTC 
and AZAN assays in reference to the left ventricular wall volume.
TFF3 expression. The relative expression of TFF3 was assessed in the ischemic myocardium and hepato-
cytes by immunoprecipitation and immunoblot analyses as  described38. Hepatic cells were isolated by colla-
genase treatment and Percoll-mediated centrifugation as  described23.
Statistics. Means and standard deviations were calculated for all measured parameters. The Student’s t-test 
was used for comparisons between two groups. The analysis of variance (ANOVA) test was used for compari-
sons between multiple groups. Post-hoc comparisons were carried out by using the Bonferroni method. Sample 
sizes were estimated by power analysis at the power level of 0.8 and α level of 0.05. A difference was considered 
statistically significant at p < 0.05.
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